Session: Joint Session: Genome Engineering for Enhanced Blood Cancer Immunotherapy
Disclosures: June: AC Immune: Membership on an entity's Board of Directors or advisory committees; BluesphereBio: Membership on an entity's Board of Directors or advisory committees; Cabaletta: Membership on an entity's Board of Directors or advisory committees; Carisma: Membership on an entity's Board of Directors or advisory committees; Cartography: Membership on an entity's Board of Directors or advisory committees; Cellares: Membership on an entity's Board of Directors or advisory committees; Celldex: Membership on an entity's Board of Directors or advisory committees; Decheng: Membership on an entity's Board of Directors or advisory committees; Poseida: Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Verismo: Membership on an entity's Board of Directors or advisory committees; WIRB-Copernicus: Membership on an entity's Board of Directors or advisory committees; Danaher: Membership on an entity's Board of Directors or advisory committees.
See more of: Scientific Program